Home

Introduction

Statistics

Authorized Vaccines

Phase III Vaccines

Phase II Vaccines

Phase I Vaccines

Preclinical Vaccines

Vaccine Safety

Vaccine Design

Literature Search

News

Data Submission

Data Exchange

Data Download

Tutorial

Links

Documentation

Updates

Acknowledgements

FAQs

Disclaimer

Contact Us

Authorized COVID-19 Vaccines

This page provides a list of COVID-19 vaccines that are approved or authorized for public use in at least one country as of July 23, 2022. This list includes vaccines that have received Emergency Use Authorization by a regulatory agency.

Contents:

1. Ad5-nCoV
2. BBIBP-CorV
3. Sputnik V
4. CoronaVac
5. EpiVacCorona
6. Comirnaty
7. Moderna COVID-19 vaccine
8. Oxford-AstraZeneca COVID-19 vaccine
9. COVAXIN
10. QazVac
11. CoviVac
12. WIBP-CorV
13. Johnson & Johnson COVID-19 vaccine
14. ZF2001
15. Abdala
16. KCONVAC
17. Chinese Academy of Medical Sciences COVID-19 vaccine
18. COVIran Barakat
19. Soberana 02
20. MVC-COV1901
21. ZyCoV-D
22. Soberana Plus
23. COVAX-19
24. NVX-CoV2373
25. Razi Cov Pars
26. Turkovac
27. Corbevax
28. CoVLP
29. Noora
30. VLA2001
31. SKYCovione

 

1. Ad5-nCoV
• Other names: Convidicea
• Manufacturer: CanSino Biologics, Beijing Institute of Biotechnology
• First authorized on: July 20, 2020
• Countries where authorized: China, Chile, and other countries
• Clinical trial ID:
• Phase III: NCT05169008
• Age subgroups: 6-17 years
• Location: Unknown
• Phase III: NCT04526990
• Age subgroups: 18 years and above
• Location: Argentina, Chile, Mexico, Pakistan, Russia
• Phase III: NCT04540419
• Age subgroups: Healthy adults aged 18-85 years
• Location: Russia
• Phase II: NCT04341389 (protocol)
• Age subgroups: Healthy adults aged 18 years and above
• Location: China
• Type: Recombinant vector vaccine
• Publications:
  • Zhu et al. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 2020; 396(10249); 479-488. [PubMed: 32702299].
  • Zhu et al. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. Lancet. 2020; 395(10240); 1845-1854. [PubMed: 32450106].
• VIOLIN: 5768
• VO: VO_0005144
2. BBIBP-CorV
• Manufacturer: Beijing Institute of Biological Products, Sinopharm
• First authorized on: July 2020
• Countries where authorized: China, Bahrain, and other countries
• Clinical trial ID:
• Phase III: NCT04917523
• Age subgroups: 3-6 years, 7-12 years, 13-17 years, 18 years and above
• Location: UAE
• Phase III: NCT04560881
• Age subgroups: 18-85 years
• Location: Argentina
• Phase III: NCT04510207
• Age subgroups: 18 years and above
• Location: Bahrain, Egypt, Jordan, UAE
• Phase III: NCT04984408
• Age subgroups: 18 years and above
• Location: Unknown
• Type: Inactivated or “killed” vaccine
• Publications:
  • Xia et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial. Lancet Infect Dis.. 2021; 21(1); 39-51. [PubMed: 33069281].
  • Wang et al. Development of an Inactivated Vaccine Candidate, BBIBP-CorV, with Potent Protection against SARS-CoV-2. Cell. 2020;182(3); 713-721. [PubMed: 32778225].
• VIOLIN: 5776
• VO: VO_0005166
3. Sputnik V
• Other names: Gam-COVID-Vac
• Manufacturer: Gamaleya Research Institute
• First authorized on: August 11, 2020
• Countries where authorized: Russia, India, and other countries
• Clinical trial ID:
• Phase II/III: NCT04954092
• Age subgroups: 12-17 years
• Location: Russia
• Phase II/III: NCT04640233
• Age subgroups: 18 years and above
• Location: India
• Phase III: NCT04741061
• Age subgroups: 18-111 years
• Location: Russia
• Phase III: NCT04530396
• Age subgroups: 18-30 years, 31-40 years, 41-50 years, 51-60 years, 61 years and above
• Location: Russia
• Phase III: NCT04564716
• Age subgroups: 18-60 years
• Location: Belarus
• Phase III: NCT04642339
• Age subgroups: 18-30 years, 31-40 years, 41-50 years, 51-60 years, 60 years and above
• Location: Venezuela
• Phase III: NCT04656613
• Age subgroups: 18-30 years, 31-40 years, 41-50 years, 51-60 years, 60 years and above
• Type: Recombinant vector vaccine
• Publications:
• Sadoff et al. Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19. N Engl J Med. 2021; 384(23); 2187-2201. [PubMed: 33882225].
• Logunov et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet. 2021; 397(10275); 671-681. [PubMed: 33545094].
• Logunov et al. Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia. Lancet. 2020; 396(10255); 887-897. [PubMed: 32896291].
• VIOLIN: 5777
• VO: VO_0005163
4. CoronaVac
• Other names: PiCoVacc
• Manufacturer: Sinovac
• First authorized on: August 28, 2020
• Countries where authorized: China, Brazil, and other countries
• Clinical trial ID:
• Phase III: NCT04992260
• Age subgroups: 6 months-17 years
• Location: Chile
• Phase III: NCT04456595 (protocol)
• Age subgroups: 18-59 years, 60 years and above
• Location: Brazil
• Phase III: NCT04508075
• Age subgroups: Clinically healthy adults aged 18-59 years
• Location: Indonesia
• Phase III: NCT04582344
• Age subgroups: Healthy adults aged 18-59 years
• Location: Turkey
• Phase III: NCT04617483
• Age subgroups: 18-25 years, 26-45 years, 46-59 years, 60 years and above
• Location: China
• Phase III: NCT04651790
• Age subgroups: 18-59 years, 60 years and above
• Location: Chile
• Phase III: NCT04800133
• Age subgroups: 11-16 years, 17 years and above
• Location: Hong Kong
• Phase III: NCT05137418
• Age subgroups: 3-11 years
• Location: China
• Phase III: NCT05077176
• Age subgroups: 18-59 years
• Location: Turkey
• Phase III: NCT05142319
• Age subgroups: 21 years and above
• Location: Singapore
• Type: Inactivated or “killed” vaccine
• Publications:
• Tanriover et al. Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey. Lancet. 2021; 398(10296); 213-222. [PMID: 34246358].
• Wu et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis. 2021; S1473-3099(20)30987-7; . [PubMed: 33548194].
• Zhang et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis. 2021; 21(2); 181-192. [PubMed: 33217362].
• Palacios et al. Double-Blind, Randomized, Placebo-Controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of treating Healthcare Professionals with the Adsorbed COVID-19 (Inactivated) Vaccine Manufactured by Sinovac - PROFISCOV: A structured summary of a study protocol for a randomised controlled trial. Trials. 2020; 21(1); 853. [PubMed: 33059771].
• Gao et al. Development of an inactivated vaccine candidate for SARS-CoV-2. Science. 2020; 369(6499); 77-81. [PubMed: 32376603].
• VIOLIN: 5761
• VO: VO_0005141
5. EpiVacCorona
• Manufacturer: FBRI State Research Center of Virology and Biotechnology
• First authorized on: October 14, 2020
• Countries where authorized: Turkmenistan, Russia, and other countries
• Clinical trial ID:
• Phase III: NCT04780035
• Age subgroups: 18 years and above
• Location: Russia
• Phase I/II: NCT04527575
• Age subgroups:
  • Phase I: 18-30 years
  • Phase II: 18-60 years
• Location: Russia
• Type: Peptide vaccine
• Publications:
• Ryzhikov et al. A single blind, placebo-controlled randomized study of the safety, reactogenicity and immunogenicity of the "EpiVacCorona" vaccine for the prevention of COVID-19, in volunteers aged 18-60 years (Phase I-II). Russian Journal of Infection and Immunity. 2021; 11(2); 283-296.
• VIOLIN: 5794
• VO: VO_0005088
6. Comirnaty
• Other names: BNT162b2, Tozinameran
• Manufacturer: BioNTech, Pfizer
• First authorized on: December 11, 2020
• Countries where authorized: USA, Canada, and other countries
• Clinical trial ID:
• Phase I/II/III: NCT04368728 (protocol)
• Age subgroups:
  • Phase I: 18-55 years, 65-85 years
  • Phase II/III: 12-15 years, 16-55 years, 56 years and above
• Location: USA, Argentina, Brazil, Germany, South Africa, Turkey
• Race/ethnicity:
• American Indian/Alaska Native: 0.6%
• Asian: 4.4%
• Black: 9.8%
• Hispanic: 26.2%
• Native Hawaiian or Other Pacific Islander: 0.2%
• White: 81.9%
• Phase II/III: NCT04754594
• Age subgroups: 18 years and above
• Location: USA, Brazil, South Africa, Spain, UK
• Phase I/II/III: NCT04816643
• Age subgroups: 6 months-2 years, 2-4 years, 5-11 years
• Location: USA
• Phase II/III: NCT05022329
• Age subgroups: 18 years and above
• Location: Canada
• Phase III: NCT05124171
• Age subgroups: 18 years and above
• Location: France
• Phase III: NCT04951323
• Age subgroups: 18 years and above
• Location: Belgium
• Phase III: NCT04955626
• Age subgroups: 16 years and above
• Location: USA, Brazil, and Canada
• Phase III: NCT04816669
• Age subgroups: 18-55 years
• Location: USA
• Phase III: NCT04805125
• Age subgroups: 18 years and above
• Location: Switzerland
• Phase III: NCT04800133
• Age subgroups: 11-16 years, 17 years and above
• Location: Hong Kong
• Phase III: NCT04713553
• Age subgroups: 18-55 years
• Phase III: NCT05048940
• Age subgroups: 18 years and above
• Location: Spain
• Phase III: TCTR20211102003
• Age subgroups: 18-80 years
• Location: Thailand
• Type: mRNA vaccine
• Publications:
  • Borobia et al. Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial. Lancet. 2021; 398(10295); 121-130. [PubMed: 34181880].
  • Frenck et al. Safety and immunogenicity of the SARS-CoV-2 BNT162b1 mRNA vaccine in younger and older Chinese adults: a randomized, placebo-controlled, double-blind phase 1 study. Nat Med. 2021; 27(6); 1062-1070. [PubMed: 33888900].
  • Li et al. Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents. N Engl J Med. 2021; 385(3); 239-250. [PubMed: 34043894].
  • Gobbi et al. Antibody Response to the BNT162b2 mRNA COVID-19 Vaccine in Subjects with Prior SARS-CoV-2 Infection. Viruses. 2021; 13(3); 422. [PubMed: 33807957].
  • Levine-Tiefenbrun et al. Initial report of decreased SARS-CoV-2 viral load after inoculation with the BNT162b2 vaccine. Nat Med. 2021; 27(5); 790-792. [PubMed: 33782619].
  • Abu Jabal et al. Impact of age, ethnicity, sex and prior infection status on immunogenicity following a single dose of the BNT162b2 mRNA COVID-19 vaccine: real-world evidence from healthcare workers, Israel, December 2020 to January 2021. Euro Surveill. 2021; 26(6); 2100096. [PubMed: 33573712].
  • Polack et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020; 383(27); 2603-2615. [PubMed: 33301246].
  • Walsh et al. Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates. N Engl J Med. 2020; 383(25); 2439-2450. [PubMed: 33053279].
  • Sahin et al. COVID-19 vaccine BNT162b1 elicits human antibody and T_H1 T-cell responses. Nature. 2020; 586(7830); 594-599. [PubMed: 32998157].
  • Mulligan et al. Phase 1/2 study of COVID-19 RNA vaccine BNT162b1 in adults. Nature. 2020; 586(7830); 589-593. [PubMed: 32785213].
• Additional links:
• FDA Briefing Document
• VIOLIN: 5784
• VO: VO_0004987
7. Moderna COVID-19 vaccine
• Other names: mRNA-1273
• Manufacturer: Moderna
• First authorized on: December 18, 2020
• Countries where authorized: USA, Canada, UK, and other countries
• Clinical trial ID:
• Phase III: NCT04470427 (protocol)
• Age subgroups: 18-64 years, 65 years and above
• Location: USA
• Race/ethnicity:
• American Indian/Alaska Native: 0.8%
• Asian: 4.7%
• Black: 9.7%
• Hispanic: 20.0%
• Native Hawaiian or Other Pacific Islander: 0.2%
• White: 79.4%
• Phase III: NCT05119855
• Age subgroups: 12-14 years
• Location: Unknown
• Phase III: NCT05142319
• Age subgroups: 21 years and above
• Location: Singapore
• Phase III: TCTR20211102003
• Age subgroups: 18-80 years
• Location: Thailand
• Phase III: NCT04860297
• Age subgroups: 18 years and above
• Location: USA
• Phase III: NCT04806113
• Age subgroups: 18 years and above
• Location: Canada
• Phase III: NCT04805125
• Age subgroups: 18 years and above
• Location: Switzerland
• Phase III: NCT04811664
• Age subgroups: 18-26 years
• Location: USA
• Phase III: NCT05048940
• Age subgroups: 18 years and above
• Location: Spain
• Phase II/III: NCT04649151
• Age subgroups: 12-17 years
• Location: USA
• Phase II/III: NCT04796896
• Age subgroups: 6 months-11 years
• Location: USA, Canada
• Phase II/III: NCT05022329
• Age subgroups: 18 years and above
• Location: Canada
• Type: mRNA vaccine
• Publications:
• Hall et al. Randomized Trial of a Third Dose of mRNA-1273 Vaccine in Transplant Recipients. N Engl J Med. 2021; ; . [PubMed: 34379917].
• Ali et al. Evaluation of mRNA-1273 SARS-CoV-2 Vaccine in Adolescents. N Engl J Med. 2021; ; . [PubMed: 34379915].
• Chu et al. A preliminary report of a randomized controlled phase 2 trial of the safety and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine. Vaccine. 2021; 39(20); 2791-2799. [PubMed: 33707061].
• Baden et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2021; 384(5); 403-416. [PubMed: 33378609].
• Anderson et al. Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults. N Engl J Med. 2020; 383(25); 2427-2438. [PubMed: 32991794].
• Additional links:
• FDA Briefing Document
• VIOLIN: 5789
• VO: VO_0005157
8. Oxford-AstraZeneca COVID-19 vaccine
• Other names: AZD1222, ChAdOx1 nCoV19, Covishield
• Manufacturer: AstraZeneca, University of Oxford
• First authorized on: December 30, 2020
• Countries where authorized: UK, India, and other countries
• Clinical trial ID:
• Phase III: NCT05142319
• Age subgroups: 21 years and above
• Location: Singapore
• Phase III: TCTR20211102003
• Age subgroups: 18-80 years
• Location: Thailand
• Phase III: NCT04864561
• Age subgroups: 18-29 years, 30 years and above
• Location: UK
• Phase III: NCT04516746 (protocol)
• Age subgroups: 18-64 years, 65 years and above
• Location: USA, Argentina, Chile, Colombia, Peru
• Phase III: EUCTR2020-005226-28
• Age subgroups: 18-55 years, 56-69 years, 70 years and above
• Location: Sweden
• Phase III: NCT04540393
• Age subgroups: 18 years and above
• Location: Russia
• Phase III: NCT04536051
• Age subgroups: 18-55 years, 56-69 years, 70 years and above
• Location: Brazil
• Phase III: ISRCTN89951424
• Age subgroups: 18-55 years
• Location: Brazil
• Phase III: NCT04800133
• Age subgroups: 11-16 years, 17 years and above
• Location: Hong Kong
• Phase II/III: TCTR20210720002
• Age subgroups: 18 years and above
• Location: Thailand
• Phase II/III: NCT05059106
• Age subgroups: 18-49 years
• Location: Brazil
• Phase II/III: CTRI/2020/08/027170
• Age subgroups: 18 years and above
• Location: India
• Phase II/III: NCT04400838
• Age subgroups: 18-55 years, 56-69 years, 70 years and above
• Location: United Kingdom
• Phase II/III: NCT04885764
• Age subgroups: 18 years and above
• Location: Egypt
• Type: Recombinant vector vaccine
• Publications:
• Stuart et al. Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial. Lancet. 2021; 399(10319); 36-49. [PubMed: 34883053].
• Flaxman et al. Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002). Lancet. 2021; 398(10304); 981-990. [PubMed: 34480858].
• Liu et al. Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial. Lancet. 2021; ; . [PubMed: 34370971].
• Borobia et al. Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial. Lancet. 2021; 398(10295); 121-130. [PubMed: 34181880].
• Madhi et al. Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant. N Engl J Med. 2021; 384(20); 1885-1898. [PubMed: 33725432.]
• Voysey et al. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. Lancet. 2021; 397(10277); 881-891. [PubMed: 33617777]
• Barrett et al. Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses. Nat Med. 2021; 27(2); 279-288. [PubMed: 33335322].
• Ewer et al. T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial. Nat Med. 2021; 27(2); 270-278. [PubMed: 33335323].
• Voysey et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021; 397(10269); 99-111. [PubMed: 33306989].
• Folegatti et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet. 2020; 396(10249); 467-478. [PubMed: 32702298].
• Additional links:
• FDA Emergency Use Authorization Review Memo
• VIOLIN: 5774
• VO: VO_0005158
9. COVAXIN
• Other names: BBV152
• Manufacturer: Bharat Biotech
• First authorized on: January 3, 2021
• Countries where authorized: India, Afghanistan, and other countries
• Clinical trial ID:
• Phase III: NCT04641481
• Age subgroups: 18 years and above
• Location: India
• Phase II/III: NCT04918797
• Age subgroups: 3-6 years, 7-12 years, 13-18 years
• Location: India
• Type: Inactivated or “killed” vaccine
• Publications:
• Ella et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial. Lancet Infect Dis. 2021; 21(7); 950-961. [PubMed: 33705727].
• Ella et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial. Lancet Infect Dis. 2021; 21(5); 637-646. [PubMed: 33485468].
• VIOLIN: 5795
• VO: VO_0004991
10. QazVac
• Other names: QazCovid-in
• Manufacturer: Research Institute for Biological Safety Problems, National Scientific Center for Phthisiopulmonology of the Republic of Kazakhstan
• First authorized on: January 13, 2021
• Countries where authorized: Kazakhstan, Kyrgyzstan
• Clinical trial ID:
• Phase III: NCT04691908
• Age subgroups: 18 years and above
• Location: Kazakhstan
• Phase I/II: NCT04530357
• Age subgroups:
• Phase I: 18-50 years
• Phase II: 18 years and above
• Location: Kazakhstan
• Type: Inactivated or "killed" vaccine
• Publications:
• Zakarya et al. Safety and immunogenicity of a QazCovid-in® inactivated whole-virion vaccine agaiinnst COVID-19 in healthy adults: A single-centre, randomised, single-blind, placebo-controlled phase 1 and an open-label phase 2 clinical trials with a 6 months follow-up in Kazakhstan. EClinicalMedicine. 2021; 39:101078. [PubMed: 34414368].
• VIOLIN: 5810
• VO: VO_0005093
11. CoviVac
• Manufacturer: Chumakov Centre at the Russian Academy of Sciences
• First authorized on: February 20, 2021
• Countries where authorized: Russia, Belarus, Cambodia
• Clinical trial ID:
• Phase III: NCT05407142
• Age subgroups: 18-60 years
• Location: Russia
• Phase I/II: NCT05046548
• Age subgroups: 18-60 years
• Location: Russia
• Type: Inactivated or “killed” vaccine
• VIOLIN: 5852
• VO: VO_0005243
12. WIBP-CorV
• Manufacturer: Wuhan Institute of Biological Products, Sinopharm
• First authorized on: February 25, 2021
• Countries where authorized: China, United Arab Emirates, and other countries
• Clinical trial ID:
• Phase III: ChiCTR2000034780
• Age subgroups: Healthy adults aged 18 years and above
• Location: UAE
• Phase III: ChiCTR2000039000
• Age subgroups: Healthy adults aged 18 years and above
• Location: Morocco
• Phase III: NCT04510207
• Age subgroups: 18 years and above
• Location: Bahrain, Egypt, Jordan, UAE
• Phase III: NCT04612972
• Age subgroups: Healthy adults aged 18 years and above
• Location: Peru
• Phase II/III: NCT04885764
• Age subgroups: 18 years and above
• Location: Egypt
• Phase I/II: ChiCTR2000031809 (protocol)
• Age subgroups: 18-59 years
• Location: China
• Type: Inactivated or “killed” vaccine
• Publications:
• Al Kaabi et al. Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: A Randomized Clinical Trial. JAMA. 2021; 326(1); 35-45. [PubMed: 34037666].
• Xia et al. Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes: Interim Analysis of 2 Randomized Clinical Trials. JAMA. 2020; 324(10); 1–10. [PubMed: 32789505].
• VIOLIN: 5775
• VO: VO_0005160
13. Johnson & Johnson COVID-19 vaccine
• Other names: Ad26.COV2.S, JNJ-78436735
• Manufacturer: Janssen Pharmaceutica
• First authorized on: February 27, 2021
• Countries where authorized: United States, Canada, and other countries
• Clinical trial ID:
• Phase III: NCT04505722 (protocol)
• Age subgroups: 18-59 years, 60 years and above
• Location: USA, Argentina, Brazil, Chile, Colombia, Mexico, Peru, Philippines, South Africa, Ukraine
• Phase III: NCT04614948
• Age subgroups: 18 years and above
• Location: USA, Belgium, Colombia, France, Germany, Philippines, South Africa, Spain, UK
• Phase III: NCT05142319
• Age subgroups: 21 years and above
• Location: Singapore
• Phase III: NCT04838795
• Age subgroups: 18 years and above
• Location: South Africa
• Phase III: NCT05048940
• Age subgroups: 18 years and above
• Location: Spain
• Phase III: NCT05047640
• Age subgroups: 18 years and above
• Location: USA
• Type: Recombinant vector vaccine
• Publications:
  • Sadoff et al. Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19. N Engl J Med. 2021; 384(23); 2187-2201. [PubMed: 33882225].
  • Sadoff et al. Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine. N Engl J Med. 2021; 384(19); 1824-1835. [PubMed: 33440088].
  • Bos et al. Ad26 vector-based COVID-19 vaccine encoding a prefusion-stabilized SARS-CoV-2 Spike immunogen induces potent humoral and cellular immune responses. NPJ Vaccines. 2020; 5; 91. [PubMed: 33083026].
  • Mercado et al. Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques. Nature. 2020; 586(7830); 583-588. [PubMed: 32731257].
• Additional links:
• FDA Briefing Document
• VIOLIN: 5782
• VO: VO_0005159
14. ZF2001
• Other names: Zifivax
• Manufacturer: Anhui Zhifei Longcom Biopharmaceutical; Institute of Microbiology, Chinese Academy of Sciences
• First authorized on: March 1, 2021
• Countries where authorized: Uzbekistan, China, and other countries
• Clinical trial ID:
• Phase III: NCT05128643
• Age subgroups: 18 years and above
• Location: China
• Phase III: NCT05091411
• Age subgroups: 18-59 years
• Location: China
• Phase III: NCT04646590
• Age subgroups: 18-59 years, 60 years and above
• Location: China
• Type: Subunit vaccine
• Publications:
• Yang et al. Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials. Lancet Infect Dis. 2021; 21(8); 1107-1119. [PubMed: 33773111].
• Dai et al. A Universal Design of Betacoronavirus Vaccines against COVID-19, MERS, and SARS. Cell. 2020; 182(3); 722-733. [PubMed: 32645327].
• VIOLIN: 5764
• VO: VO_0005142
15. Abdala
• Other names: CIGB-66
• Manufacturer: Center for Genetic Engineering and Biotechnology (CIGB)
• First authorized on: May 12, 2021
• Countries where authorized: Cuba, Venezuela, and other countries
• Clinical trial ID:
• Phase III: RPCEC00000359
• Age subgroups: 19-80 years
• Location: Cuba
• Phase I/II: RPCEC00000346
• Age subgroups:
Phase I: 19-54 years
Phase II: 19-80 years
• Location: Cuba
• Type: Subunit vaccine
• VIOLIN: 5803
• VO: VO_0005082
16. KCONVAC
• Manufacturer: Shenzhen Kangtai Biological Products Co., Ltd.; Beijing Minhai Biotechnology Co.
• First authorized on: May 14, 2021
• Countries where authorized: China, Indonesia
• Clinical trial ID:
• Phase III: NCT04852705
• Age subgroups: 18 years and above
• Location: China
• Phase II: ChiCTR2000039462
• Age subgroups: 18 years and above
• Location: China
• Phase I: NCT04758273
• Age subgroups: 18 years and above
• Location: China
• Type: Inactivated or "killed" vaccine
• Publications:
• Pan et al. Immunogenicity and safety of a SARS-CoV-2 inactivated vaccine in healthy adults: randomized, double-blind, and placebo-controlled phase 1 and phase 2 clinical trials. Chin Med J (Engl). 2021; 134(11); 1289-1298. [PubMed: 33928916].
• VIOLIN: 5805
• VO: VO_0005084
17. Chinese Academy of Medical Sciences COVID-19 vaccine
• Other names: Covidful, IMBCAMS COVID-19 vaccine
• Manufacturer: Institute of Medical Biology, Chinese Academy of Medical Sciences
• First authorized on: June 9, 2021
• Countries where authorized: China
• Clinical trial ID:
• Phase III: NCT04659239
• Age subgroups: 18 years and above
• Location: Brazil, Malaysia
• Phase III: NCT05033847
• Age subgroups: 18 years and above
• Location: UAE
• Phase III: NCT05163652
• Age subgroups: 18 years and above
• Location: China
• Phase III: NCT05164731
• Age subgroups: 18 years and above
• Location: China
• Type: Inactivated or “killed” vaccine
• Publications:
• Pu et al. The safety and immunogenicity of an inactivated SARS-CoV-2 vaccine in Chinese adults aged 18-59 years: A phase I randomized, double-blinded, controlled trial. Vaccine. 2021; 39(20); 2746-2754. [PubMed: 33875266].
• VIOLIN: 5785
• VO: VO_0005167
18. COVIran Barakat
• Manufacturer: Shifa Pharmed Industrial Co
• First authorized on: June 13, 2021
• Countries where authorized: Iran, Nicaragua
• Clinical trial ID:
• Phase II/III: IRCT20201202049567N3
• Age subgroups: 18-75 years
• Location: Iran
• Phase I: IRCT20201202049567N1
• Age subgroups: 18-50 years
• Location: Iran
• Type: Inactivated or "killed" vaccine
• VIOLIN: 5815
• VO: VO_0005229
19. Soberana 02
• Other names: FINLAY-FR-2
• Manufacturer: Instituto Finlay de Vacunas, Cuba
• First authorized on: June 29, 2021
• Countries where authorized: Iran, Cuba, Nicaragua, Venezuela
• Clinical trial ID:
• Phase III: IFV/COR/09
• Age subgroups: 19-80 years
• Location: Cuba
• Phase I/II: IFV/COR/04
• Age subgroups: 19-59 years, 60-80 years
• Location: Cuba
• Phase II: IFV/COR/08
• Age subgroups: 19-80 years
• Location: Cuba
• Type: Subunit vaccine
• VIOLIN: 5814
• VO: VO_0005097
20. MVC-COV1901
• Manufacturer: Medigen Vaccine Biologics, Dynavax, National Institute of Allergy and Infectious Diseases (NIAID)
• First authorized on: July 19, 2021
• Countries where authorized: Taiwan, Paraguay
• Clinical trial ID:
• Phase III: NCT05011526
• Age subgroups: 18 years and above
• Phase III: ISRCTN15779782
• Age subgroups: 16 years and above
• Location: Switzerland
• Phase II: NCT04951388
• Age subgroups: 12-17 years
• Location: Taiwan
• Phase II: NCT04951388
• Age subgroups: 12-17 years
• Location: Taiwan
• Phase II: NCT04695652
• Age subgroups: 20-64 years, 65 years and above
• Location: Taiwan, Vietnam
• Phase II: NCT04822025
• Age subgroups: 65 years and above
• Location: Taiwan
• Type: Subunit vaccine
• VIOLIN: 5828
• VO: VO_0005192
21. ZyCoV-D
• Manufacturer: Zydus Cadila
• First authorized on: August 20, 2021
• Countries where authorized: India
• Clinical trial ID:
• Phase III: CTRI/2021/01/030416
• Age subgroups: 12 years and above
• Location: India
• Phase I/II: CTRI/2020/07/026352
• Age subgroups:
• Phase I: 18-45 years
• Phase II: 18-79 years
• Location: Australia
• Type: DNA vaccine
• VIOLIN: 5778
• VO: VO_0005162
22. Soberana Plus
• Other names: FINLAY-FR-1A
• Manufacturer: Instituto Finlay de Vacunas, Cuba
• First authorized on: August 20, 2021
• Countries where authorized: Cuba
• Clinical trial ID:
• Phase II: IFV/COR/11
• Age subgroups: 19-80 years
• Location: Cuba
• Phase I/II: IFV/COR/04
• Age subgroups: 19-59 years, 60-80 years
• Location: Cuba
• Type: Subunit vaccine
• Publications:
• Ochoa-Azze et al. Safety and immunogenicity of the FINLAY-FR-1A vaccine in COVID-19 convalescent participants: an open-label phase 2a and double-blind, randomised, placebo-controlled, phase 2b, seamless, clinical trial. Lancet Respir Med. 2022; S2213-2600(22)00100-X. [PubMed: 35691295].
• VIOLIN: 5853
• VO: VO_0005244
23. COVAX-19
• Other names: SpikoGen
• Manufacturer: Vaxine, Cinnagen
• First authorized on: October 6, 2021
• Countries where authorized: Iran
• Clinical trial ID:
• Phase III: NCT05005559
• Age subgroups: 18-49 years
• Location: Iran
• Phase II/III: NCT05148871
• Age subgroups: 18 years and above
• Location: Australia
• Phase II: NCT04944368
• Age subgroups: 18 years and above
• Location: Iran
• Phase I: NCT04453852
• Age subgroups: 18-65 years
• Location: Australia
• Type: Subunit vaccine
• VIOLIN: 5829
• VO: VO_0005193
24. NVX-CoV2373
• Other names: Nuvaxovid, Covovax
• Manufacturer: Novavax
• First authorized on: November 1, 2021
• Countries where authorized: Australia, Canada, and other countries
• Clinical trial ID:
• Phase III: NCT04583995 (protocol)
• Age subgroups: 18-64 years, 65-84 years
• Location: UK
• Phase III: NCT04611802
• Age subgroups: 18 years and above
• Location: USA, Mexico, Puerto Rico
• Type: Subunit vaccine
• Publications:
• Shinde et al. Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant. N Engl J Med. 2021; 384(20); 1899–909. [PubMed: 33951374].
• Guebre-Xabier et al. NVX-CoV2373 vaccine protects cynomolgus macaque upper and lower airways against SARS-CoV-2 challenge. Vaccine. 2020; 38(50); 7892-7896. [PubMed: 33139139].
• Keech et al. Phase 1-2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine. N Engl J Med. 2020; 383(24); 2320-2332. [PubMed: 32877576].
• VIOLIN: 5791
• VO: VO_0005155
25. Razi Cov Pars
• Manufacturer: Razi Vaccine and Serum Research Institute
• First authorized on: November 1, 2021
• Countries where authorized: Iran
• Clinical trial ID:
• Phase III: IRCT20210206050259N3
• Age subgroups: 18 years and above
• Location: Iran
• Phase II: IRCT20201214049709N2
• Age subgroups: 18-70 years
• Location: Iran
• Phase I: IRCT20201214049709N1
• Age subgroups: 18-55 years
• Location: Iran
• Type: Subunit vaccine
• VIOLIN: 5779
• VO: VO_0005226
26. Turkovac
• Other names: ERUCOV-VAC
• Manufacturer: Erciyes University
• First authorized on: December 22, 2021
• Countries where authorized: Turkey
• Clinical trial ID:
• Phase III: NCT04942405
• Age subgroups: 18-55 years
• Location: Turkey
• Phase II: NCT04824391
• Age subgroups: 18-64 years
• Location: Turkey
• Phase I: NCT04691947
• Age subgroups: 18-55 years
• Location: Turkey
• Type: Inactivated or "killed" vaccine
• VIOLIN: 5836
• VO: VO_0005188
27. Corbevax
• Other names: BECOV2D, Biological E COVID-19 vaccine
• Manufacturer: Biological E
• First authorized on: December 28, 2021
• Countries where authorized: India, Botswana
• Clinical trial ID:
• Phase III: CTRI/2021/08/036074
• Age subgroups: 18-80 years
• Location: India
• Phase I/II: CTRI/2020/11/029032
• Age subgroups:
• Phase I: 18-55 years
• Phase II: 18-65 years
• Location: India
• Type: Subunit vaccine
• VIOLIN: 5802
• VO: VO_0005081
28. CoVLP
• Manufacturer: Medicago Inc.
• First authorized on: February 24, 2022
• Countries where authorized: Canada
• Clinical trial ID:
• Phase III: NCT05040789
• Age subgroups: 18-49 years
• Location: Canada
• Phase II/III: NCT04636697
• Age subgroups: 18-64 years, 65 years and above
• Location: Canada
• Type: Virus-like particle
• Publications:
• Hager et al. Efficacy and Safety of a Recombinant Plant-Based Adjuvanted Covid-19 Vaccine. N Engl J Med. 2022; 386(22); 2084-2096. [PubMed: 35507508].
• VIOLIN: 5796
• VO: VO_0004992
29. Noora
• Manufacturer: Bagheiat-allah University of Medical Sciences
• First authorized on: March 1, 2022
• Countries where authorized: Iran
• Clinical trial ID:
• Phase III: IRCT20210620051639N3
• Age subgroups: 18 years and above
• Location: Iran
• Phase II: IRCT20210620051639N2
• Age subgroups: 18-40 years
• Location: Iran
• Phase I: IRCT20210620051639N1
• Age subgroups: 18-50 years
• Location: Iran
• Type: Subunit vaccine
• VIOLIN: 5877
• VO: VO_0005316
30. VLA2001
• Manufacturer: Valneva, National Institute for Health Research (UK)
• First authorized on: April 15, 2022
• Countries where authorized: United Kingdom, Austria, and other countries
• Clinical trial ID:
• Phase III: NCT04956224
• Age subgroups:
• Cohort 1: 56 years and above
• Cohort 2: 12 years and above
• Location: New Zealand
• Phase III: NCT04864561
• Age subgroups: 18-29 years, 30 years and above
• Location: UK
• Phase I/II: NCT04671017
• Age subgroups: 18-55 years
• Location: UK
• Type: Inactivated or "killed" vaccine
• VIOLIN: 5816
• VO: VO_0005099
31. SKYCovione
• Other names: GBP510
• Manufacturer: SK Bioscience Co., Ltd.
• First authorized on: June 29, 2022
• Countries where authorized: South Korea
• Clinical trial ID:
• Phase III: NCT05007951
• Age subgroups: 18 years and above
• Location: South Korea, New Zealand, Philippines, Thailand, Ukraine, Vietnam
• Phase I/II: NCT04742738
• Age subgroups:
• Phase I: 19-55 years
• Phase II: 19-85 years
• Location: South Korea
• Phase I/II: NCT04750343
• Age subgroups:
• Phase I: 19-55 years
• Phase II: 19-85 years
• Location: South Korea
• Type: Subunit vaccine
• VIOLIN: 5831
• VO: VO_0005197

 

Provenance: All data in Cov19VaxKB originates from manual curation of various resources, including the WHO's COVID-19 Vaccine Tracker.

Note: The page was updated on July 23, 2022.  Please provide us with any new information that you believe would be useful if included on the website.